Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IXHL with free AI briefings, catalyst countdowns, and dilution alerts.

IXHL · Incannex Healthcare Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$68.3M Cash on Hand
CF+ Cash Runway
3.1% Short Interest
$18.08 Analyst Target (2)
Follow IXHL by email Get an email when IXHL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IXHL, unsubscribe in one click. Privacy

📣 What IXHL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
IHL-42X (Optimal Dose) Obstructive Sleep Apnea Phase 2/3 · NCT06146101 Completed
Hydroxychloroquine Rheumatoid Arthritis Phase 2 · NCT05942911 Terminated
IHL-675A Rheumatoid Arthritis Phase 2 · NCT05942911 Terminated
IHL42X Obstructive Sleep Apnea Phase 1 · NCT05857384 Completed

Also used in these trials (approved or third-party drugs, not IXHL's own candidates): Acetazolamide, Dronabinol, Cannabidiol.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IXHL holds $68.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IXHL files for a raise →

👥 Who Owns IXHL

Insiders 100% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Joel Latham
CEO and President, Director
Insider 24,186,177 192.78% 2025-11-14
Troy Valentine
Director
Insider 12,339,120 98.35% 2025-11-14
George Anastassov
Director
Insider 2,456,677 19.58% 2025-11-14
Peter Widdows
Director
Insider 1,957,803 15.60% 2025-11-14
Robert Clark
Director
Insider 1,786,956 14.24% 2025-11-14
Joseph Swan
CFO, Treasurer and Secretary
Insider 921,358 7.34% 2025-11-14
Polar Asset Management Partners Inc. Institution (13G, 5%+) 900,000 7.17% 2026-06-30
Lekhram Changoer
Chief Technology Officer
Insider 639,549 5.10% 2023-11-28
AdvisorShares Investments, LLC Institution (13F) 168,305 1.34% 2026-09-30
LPL Financial LLC Institution (13F) 153,139 1.22% 2026-09-30
Luigi M. Barbato
Chief Medical Officer
Insider 100,476 0.80% 2024-10-23
Citadel Advisors Llc Institution (13F) 53,635 0.43% 2026-09-30

Share count 12,546,030 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2025-11-14
filed 2025-11-14
Valentine Troy
Award (A) 11,302,608 – 12,001,858
2025-11-14
filed 2025-11-14
Clark Robert
Award (A) 1,686,956 – 1,786,956
2025-11-14
filed 2025-11-14
Widdows Peter
Award (A) 1,686,956 – 1,957,803
2025-11-14
filed 2025-11-14
Swan Joseph
Award (A) 869,565 – 921,358
2025-11-14
filed 2025-11-14
Latham Joel
Award (A) 22,608,692 – 24,186,177

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full IXHL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IXHL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.